Endoscopic ultrasound in the diagnosis and management of carcinoma pancreas

According to the US SEER database, pancreatic cancer accounts for 3% of all new cancer cases. According to cases from 2008 to 2012, the number of new cases of pancreatic cancer per 100,000 men and women is 12.4 per year, and the number of deaths is 10.9 per 100,000 people. Men become more common and more common than women as age goes on. The median age of diagnosis was 71 years and the median age of death was 73 years. It is estimated that 48,960 cases of pancreatic cancer will be newly developed in 2015, with an estimated 40,560 deaths due to this disease. Using a statistical model for analysis, the incidence of newly developed pancreatic cancer cases increased by an average of 0.8% per year. The death rate after 10 years is stable and the 5-year survival rate is less than 5% - 7.2% [1, 2]. This is a serious problem of illness.

In a recent study, the role of endoscopic ultrasound (EUS) in the evaluation of pancreatic cancer was suggested as an independent predictor of survival and improvement in patients with focal pancreatic cancer [3]. We will focus on all aspects of the role of EUS in the treatment of pancreatic cancer.

Preoperative diagnostic imaging techniques improved the early diagnosis of resectable stages, including pancreatic-specific computed tomography (CT), magnetic resonance imaging (MRI), and endoscopic ultrasound (EUS) . Because resectionability and treatment decisions should be made by oncologists, radiologists, and gastroenterologists, these advanced imaging techniques are more selective methods for timely surgical procedures make it possible. The house and the team of hepatobiliary surgeons did. Imaging using dedicated pancreatic magnetic resonance imaging (MRI) and CT protocol helps to accurately classify and determine the excisable state of the PDAC. Here we explain various diagnostic methods for diagnosing pancreatic tumor.

Pancreatic cancer is a fatal cancer. Most patients are being diagnosed as in a progressive phase of progress. Despite improvements in diagnostic methods and management strategies, including surgical methods and chemotherapy, pancreatic cancer results are still bad. Ultrasound endoscopy (EUS) is an important imaging tool for pancreatic cancer. Resected pancreatic cancer and other cancer specimens have been used for decades to identify tissue biomarkers or genomics for accurate treatment; however, only 20% of patients have surgery. Cancer is ineffective. As needle technology advances, tumor specimens can be obtained at the time of tissue diagnosis. Tumor tissue can be used for the development of individualized cancer therapies such as full-exosome sequencing and global genome analysis of pancreatic cancer, development of tissue biomarkers, targeted mutation assays for fine chemotherapy . View full text